Target Name: ELAC2
NCBI ID: G60528
Review Report on ELAC2 Target / Biomarker Content of Review Report on ELAC2 Target / Biomarker
ELAC2
Other Name(s): HPC2 | Putative prostate cancer susceptibility protein HPC2/ELAC2 | ElaC homolog protein 2 | putative prostate cancer susceptibility protein HPC2/ELAC2 | RNZ2_HUMAN | Zinc phosphodiesterase ELAC protein 2 (isoform 1) | elaC ribonuclease Z 2 | COXPD17 | ELAC2 variant 1 | ELAC2 variant 2 | ElaC ribonuclease Z 2, transcript variant 1 | tRNA 3 endonuclease 2 | ElaC homolog 2 | Heredity prostate cancer protein 2 | Ribonuclease Z 2 | ELC2 | elaC homolog protein 2 | heredity prostate cancer protein 2 | tRNase Z 2 | Zinc phosphodiesterase ELAC protein 2 | ElaC ribonuclease Z 2, transcript variant 2 | ElaC-like protein 2 | RNase Z 2 | tRNase Z (long form) | elaC-like protein 2 | elaC homolog 2 | Zinc phosphodiesterase ELAC protein 2 (isoform 2) | ribonuclease Z 2

ELAC2: Key Protein Regulating ER Function

ELAC2 (Endoplasmic Reticulum-Antigen-2) is a protein that is expressed in most tissues of the body. It is a key protein that is involved in the regulation of endoplasmic reticulum (ER) and is a potential drug target and biomarker.

The ER is a protein structure that spans the length of the cell and is responsible for the sorting and delivery of proteins to their final destinations. ER dysfunction has been implicated in a wide range of diseases, including neurodegenerative disorders, cancer, and autoimmune diseases.

ELAC2 is a member of the ER protein family and is expressed in most tissues of the body. It is a 120-kDa protein that consists of two distinct domains: an N-terminus and a C-terminus. The N-terminus of ELAC2 contains a 21-amino acid residue that is involved in the formation of a disulfide bond. The C-terminus of ELAC2 contains a 61-amino acid residue that is involved in the formation of a disulfide bond.

ELAC2 is involved in the regulation of ER function and has been shown to play a role in the sorting and delivery of proteins to their final destinations. For example, studies have shown that ELAC2 is involved in the delivery of proteins to the endoplasmic reticulum, and that it helps to ensure that proteins are properly sorted and delivered to their final destinations.

In addition to its role in ER function, ELAC2 has also been shown to play a role in the regulation of cellular processes. For example, studies have shown that ELAC2 is involved in the regulation of cell growth, and that it helps to ensure that cells grow and divide in a controlled manner.

ELAC2 is also a potential drug target and biomarker. Its involvement in ER function and regulation makes it an attractive target for drugs that are designed to modulate ER function or to interfere with its activity. Additionally, its expression is often altered in a wide range of diseases, including neurodegenerative disorders, cancer, and autoimmune diseases, which makes it an attractive biomarker for these conditions.

In conclusion, ELAC2 is a protein that is involved in the regulation of endoplasmic reticulum (ER) function and has been shown to play a role in the sorting and delivery of proteins to their final destinations. Its potential as a drug target and biomarker makes it an attractive target for the development of new therapies for a wide range of diseases.

Protein Name: ElaC Ribonuclease Z 2

Functions: Zinc phosphodiesterase, which displays mitochondrial tRNA 3'-processing endonuclease activity. Involved in tRNA maturation, by removing a 3'-trailer from precursor tRNA (PubMed:21593607). Associates with mitochondrial DNA complexes at the nucleoids to initiate RNA processing and ribosome assembly (PubMed:24703694)

The "ELAC2 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about ELAC2 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets

ELANE | ELAPOR1 | ELAPOR2 | Elastase | ELAVL1 | ELAVL2 | ELAVL3 | ELAVL4 | ELDR | ELF1 | ELF2 | ELF2P4 | ELF3 | ELF3-AS1 | ELF4 | ELF5 | ELFN1 | ELFN1-AS1 | ELFN2 | ELK1 | ELK2AP | ELK3 | ELK4 | ELL | ELL2 | ELL2P1 | ELL3 | ELMO1 | ELMO2 | ELMO3 | ELMOD1 | ELMOD2 | ELMOD3 | ELN | ELOA | ELOA-AS1 | ELOA2 | ELOA3BP | ELOA3DP | ELOA3P | ELOB | ELOC | ELOF1 | Elongation Factor 1 Complex | Elongation of very long chain fatty acids protein | Elongin (SIII) complex | ELOVL1 | ELOVL2 | ELOVL2-AS1 | ELOVL3 | ELOVL4 | ELOVL5 | ELOVL6 | ELOVL7 | ELP1 | ELP2 | ELP3 | ELP4 | ELP5 | ELP6 | ELSPBP1 | EMB | EMBP1 | EMC1 | EMC1-AS1 | EMC10 | EMC2 | EMC3 | EMC3-AS1 | EMC4 | EMC6 | EMC7 | EMC8 | EMC9 | EMCN | EMD | EME1 | EME2 | EMG1 | EMID1 | EMILIN1 | EMILIN2 | EML1 | EML2 | EML2-AS1 | EML3 | EML4 | EML4-AS1 | EML5 | EML6 | EMP1 | EMP2 | EMP2P1 | EMP3 | EMSLR | EMSY | EMX1 | EMX2 | EMX2OS | EN1